Mediland Pharm Limited reported consolidated earnings results for the half year ended December 31, 2020. For the period, the company revenue of $726,641 against $19,393,774 a year ago. Loss after income tax expense for the half year attributable to members of the company was $5,511,806 against $795,249 a year ago. Total comprehensive income for the half year attributable to members of company was $5,507,429 against $774,689 a year ago. Basic and diluted loss per share was 1.76 cents against 0.25 cents a year ago.